INTERCEPT PHARMACEUTICALS INC 4
4 · INTERCEPT PHARMACEUTICALS INC · Filed Oct 11, 2013
Insider Transaction Report
Form 4
TALLARIGO LORENZO
Director
Transactions
- Exercise/Conversion
Common Stock
2013-10-10+1,471→ 3,111 total - Exercise/Conversion
Restricted Stock Units
2013-10-10−1,471→ 1,471 total→ Common stock (1,471 underlying)
Holdings
- 7,187,217(indirect: See Footnote)
Common Stock
Footnotes (3)
- [F1]Each restricted stock unit ("RSU") represents the contingent right to receive one share of common stock upon vesting of the unit.
- [F2]On November 16, 2012, the reporting person was granted 2,942 RSUs. The vesting of all RSUs granted to Dr. Tallarigo was suspended until October 10, 2013, at which time all RSUs that would have vested on or prior to such date vested. The remainder of the shares underlying the RSUs will vest pro rata until August 9, 2014, with the RSUs vesting on November 9, 2013 and then on every subsequent three-month anniversary of such date, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan.
- [F3]Held by Genextra S.p.A. Dr. Tallarigo is the chief executive officer of Genextra S.p.A. and, in such capacity, Dr. Tallarigo exercises voting control over the shares of common stock owned by Genextra S.p.A. and investment control over such shares as authorized by the board of directors of Genextra S.p.A. Dr. Tallarigo disclaims beneficial ownership with respect to any such shares, except to the extent of his pecuniary interest therein, if any.